ABCL
Abcellera Biologics Inc
NASDAQ · Life Sciences Tools & Services
$3.16
+0.38 (+13.67%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 29.33M | 68.99M | 394.89M | 396.65M | 320.81M |
| Net Income | -165,622,080 | -350,564,139 | 57.89M | 43.78M | 34.81M |
| EPS | — | — | — | — | — |
| Profit Margin | -564.8% | -536.6% | 14.7% | 11.0% | 10.9% |
| Rev Growth | -57.5% | -57.5% | +5.6% | +18.5% | +8.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 218.08M | 222.59M | 227.01M |
| Total Equity | — | — | 699.66M | 817.40M | 806.57M |
| D/E Ratio | — | — | 0.31 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -168,226,294 | -375,858,370 | 91.93M | 99.33M | 83.21M |
| Free Cash Flow | — | — | 65.77M | 67.30M | 42.05M |